Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin-18.2-positive cells through an immune effector mechanism.Zolbetuximab is used in the study of gastrointestinal adenocarcinomas and pancreatic tumors.

IMAB362 (Zolbetuximab) mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.[2]

IMAB362 (Zolbetuximab) (33, 100, 300, 600, and 1000 mg/m2; adult patients with advanced gastric or gastro-oesophageal junction cancer) was generally well tolerated at all doses, with gastrointestinal toxicities being the most commonly observed treatment-related adverse events. IMAB362 mean half-life ranged from 13 to 24 d. While most patients showed progressive disease at weeks 4-5 after a single intravenous IMAB362 infusion, one patient in the 600 mg/m2 dose group achieved and maintained stable disease for approximately 2 months post-infusion.[2]